Lynn Kirkpatrick

Former Co-founder of ProlX Pharmaceuticals and Professor of Chemistry and Biochemistry at the University of Regina, Canada, Lynn Kirkpatrick has spent over 30 years in cancer drug discovery and development. From 1999 to 2006 Dr. Kirkpatrick was CEO of ProlX Pharmaceuticals, taking three small molecules from bench to bedside. When ProlX was acquired by Biomira Inc., a publicly traded company, she became the Chief Scientific Officer of the merged company which changed its name to Oncothyreon, Inc. in 2007. Following her resignation from Oncothyreon in 2009, Dr. Kirkpatrick co-founded PHusis Therapeutics with Drs. Powis, Meuillet and Zhang. Dr. Kirkpatrick received her PhD from the University of Saskatchewan and did post-doctoral research at Yale University School of Medicine. She has published extensively in the area of targeted cancer drug discovery and development with over 120 papers and presentaions and holds numerous patents for novel cancer drugs.